阿帕替尼在非小细胞肺癌中的研究进展

Progress of Apatinib in Treatment of Non-small Cell Lung Cancer

非小细胞肺癌(non-small cell lung cancer, NSCLC)是我国死亡率最高的恶性肿瘤之一。近年来,NSCLC的治疗取得了长足的进步,众多新药的问世显著改善了晚期NSCLC患者的生存期。甲磺酸阿帕替尼是一种新型口服小分子血管内皮生长因子受体酪氨酸激酶抑制剂,目前已被批准用于胃癌的三线治疗。目前,大量研究证实阿帕替尼单药治疗晚期NSCLC也有较好效果。临床前研究提示,阿帕替尼还可改善化疗和EGFR TKI耐药,因此,阿帕替尼联合化疗或EGFR TKI治疗晚期NSCLC也进行了广泛的探索。现就阿帕替尼在NSCLC的基础及临床研究中的进展作一综述。

Non-small cell lung cancer(NSCLC)is the malignant tumor with the highest mortality in China.In recent years,considerable progress has been made in the treatment of NSCLC.The advent of numerous new drugs has significantly improved the survival of patients with advanced NSCLC.Apatinib mesylate is a novel oral small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor that has been approved for the third-line treatment of gastric cancer.At present,increased evidence confirmed that apatinib monotherapy has well efficacy on advanced NSCLC.Preclinical studies suggest that apatinib could reverse chemotherapy and EGFR TKI resistance.Therefore,apatinib combined with chemotherapy or EGFR TKI for advanced NSCLC has also been extensively explored.This article will give an overview of the basic and clinical progress of apatinib on NSCLC.